We Focus on the Small Intestine to Affect Big Change for Patients
Evelo is a clinical-stage biotech with a vision to dramatically improve healthcare.
Our novel platform harnesses the small intestinal axis, SINTAX, to create a new class of effective, safe and well-tolerated, oral and convenient, and affordable medicines with the potential to treat hundreds of millions of people at all stages of inflammatory disease. We are building our company with exceptional people who move beyond “good enough” to make a profound impact.
- To disrupt, eradicate, uproot
Evolution has put the small intestine at the center of biology.
Addressing the Worldwide Inflammation Crisis
Inflammatory diseases represent a growing global healthcare crisis, with 30 percent of people in the world suffering from systemic inflammation, yet less than one percent of the world’s population currently has access to effective, safe and well-tolerated, oral and convenient, and affordable medicines that can treat diseases caused by inflammation. Our work aims to harness SINTAX to modulate the body’s immune system – resolving inflammation to treat diseases such as psoriasis, atopic dermatitis, asthma, food allergies, arthritis, inflammatory bowel disease, and neuroinflammatory diseases.
The Potential to Treat Inflammatory Diseases
Our product candidates are pharmaceutical preparations of single strains of non-live microbes or microbial extracellular vesicles (EVs) that are taken orally and are able to treat inflammation throughout the body. In clinical studies to- date, we have observed our lead product candidate EDP1815 to be well-tolerated and comparable to placebo.
We are developing EDP1815, currently in late-stage development for psoriasis and atopic dermatitis, and EDP2939, about to enter the clinic to treat inflammatory diseases. Evelo is also advancing additional product candidates in other disease areas.